Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 77

1.

A Novel Mass Spectrometry Platform for Multiplexed N-Glycoprotein Biomarker Discovery from Patient Biofluids by Antibody Panel Based N-Glycan Imaging.

Black AP, Liang H, West CA, Wang M, Herrera HP, Haab BB, Angel PM, Drake RR, Mehta AS.

Anal Chem. 2019 Jul 2;91(13):8429-8435. doi: 10.1021/acs.analchem.9b01445. Epub 2019 Jun 20.

PMID:
31177770
2.

The sTRA Plasma Biomarker: Blinded Validation of Improved Accuracy Over CA19-9 in Pancreatic Cancer Diagnosis.

Staal B, Liu Y, Barnett D, Hsueh P, He Z, Gao C, Partyka K, Hurd MW, Singhi AD, Drake RR, Huang Y, Maitra A, Brand RE, Haab BB.

Clin Cancer Res. 2019 May 1;25(9):2745-2754. doi: 10.1158/1078-0432.CCR-18-3310. Epub 2019 Jan 7.

PMID:
30617132
3.

The CA19-9 and Sialyl-TRA Antigens Define Separate Subpopulations of Pancreatic Cancer Cells.

Barnett D, Liu Y, Partyka K, Huang Y, Tang H, Hostetter G, Brand RE, Singhi AD, Drake RR, Haab BB.

Sci Rep. 2017 Jun 22;7(1):4020. doi: 10.1038/s41598-017-04164-z.

4.

A Gastric Glycoform of MUC5AC Is a Biomarker of Mucinous Cysts of the Pancreas.

Sinha J, Cao Z, Dai J, Tang H, Partyka K, Hostetter G, Simeone DM, Feng Z, Allen PJ, Brand RE, Haab BB.

PLoS One. 2016 Dec 19;11(12):e0167070. doi: 10.1371/journal.pone.0167070. eCollection 2016.

5.

Characterizing Protein Glycosylation through On-Chip Glycan Modification and Probing.

Reatini BS, Ensink E, Liau B, Sinha JY, Powers TW, Partyka K, Bern M, Brand RE, Rudd PM, Kletter D, Drake R, Haab BB.

Anal Chem. 2016 Dec 6;88(23):11584-11592. Epub 2016 Nov 15.

6.

Glycans related to the CA19-9 antigen are elevated in distinct subsets of pancreatic cancers and improve diagnostic accuracy over CA19-9.

Tang H, Partyka K, Hsueh P, Sinha JY, Kletter D, Zeh H, Huang Y, Brand RE, Haab BB.

Cell Mol Gastroenterol Hepatol. 2016 Feb 1;2(2):201-221.e15.

7.

Multiplexed autoantigen microarrays identify HLA as a key driver of anti-desmoglein and -non-desmoglein reactivities in pemphigus.

Sajda T, Hazelton J, Patel M, Seiffert-Sinha K, Steinman L, Robinson W, Haab BB, Sinha AA.

Proc Natl Acad Sci U S A. 2016 Feb 16;113(7):1859-64. doi: 10.1073/pnas.1525448113. Epub 2016 Feb 1.

8.

Definitive Characterization of CA 19-9 in Resectable Pancreatic Cancer Using a Reference Set of Serum and Plasma Specimens.

Haab BB, Huang Y, Balasenthil S, Partyka K, Tang H, Anderson M, Allen P, Sasson A, Zeh H, Kaul K, Kletter D, Ge S, Bern M, Kwon R, Blasutig I, Srivastava S, Frazier ML, Sen S, Hollingsworth MA, Rinaudo JA, Killary AM, Brand RE.

PLoS One. 2015 Oct 2;10(10):e0139049. doi: 10.1371/journal.pone.0139049. eCollection 2015.

9.

Segment and fit thresholding: a new method for image analysis applied to microarray and immunofluorescence data.

Ensink E, Sinha J, Sinha A, Tang H, Calderone HM, Hostetter G, Winter J, Cherba D, Brand RE, Allen PJ, Sempere LF, Haab BB.

Anal Chem. 2015 Oct 6;87(19):9715-21. doi: 10.1021/acs.analchem.5b03159. Epub 2015 Sep 11.

10.

Upregulation of glycans containing 3' fucose in a subset of pancreatic cancers uncovered using fusion-tagged lectins.

Singh S, Pal K, Yadav J, Tang H, Partyka K, Kletter D, Hsueh P, Ensink E, Kc B, Hostetter G, Xu HE, Bern M, Smith DF, Mehta AS, Brand R, Melcher K, Haab BB.

J Proteome Res. 2015 Jun 5;14(6):2594-605. doi: 10.1021/acs.jproteome.5b00142. Epub 2015 May 12.

11.

Exploring the specificities of glycan-binding proteins using glycan array data and the GlycoSearch software.

Kletter D, Curnutte B, Maupin KA, Bern M, Haab BB.

Methods Mol Biol. 2015;1273:203-14. doi: 10.1007/978-1-4939-2343-4_15.

12.

Glycan motif profiling reveals plasma sialyl-lewis x elevations in pancreatic cancers that are negative for sialyl-lewis A.

Tang H, Singh S, Partyka K, Kletter D, Hsueh P, Yadav J, Ensink E, Bern M, Hostetter G, Hartman D, Huang Y, Brand RE, Haab BB.

Mol Cell Proteomics. 2015 May;14(5):1323-33. doi: 10.1074/mcp.M114.047837. Epub 2015 Mar 2.

13.

Detection of distinct glycosylation patterns on human γ-glutamyl transpeptidase 1 using antibody-lectin sandwich array (ALSA) technology.

West MB, Partyka K, Feasley CL, Maupin KA, Goppallawa I, West CM, Haab BB, Hanigan MH.

BMC Biotechnol. 2014 Dec 6;14:101. doi: 10.1186/s12896-014-0101-0.

14.

MALDI imaging mass spectrometry profiling of N-glycans in formalin-fixed paraffin embedded clinical tissue blocks and tissue microarrays.

Powers TW, Neely BA, Shao Y, Tang H, Troyer DA, Mehta AS, Haab BB, Drake RR.

PLoS One. 2014 Sep 3;9(9):e106255. doi: 10.1371/journal.pone.0106255. eCollection 2014.

15.

Mesenchymal-like pancreatic cancer cells harbor specific genomic alterations more frequently than their epithelial-like counterparts.

Sinha A, Cherba D, Bartlam H, Lenkiewicz E, Evers L, Barrett MT, Haab BB.

Mol Oncol. 2014 Oct;8(7):1253-65. doi: 10.1016/j.molonc.2014.04.007. Epub 2014 May 2.

16.

Using antibody arrays to measure protein abundance and glycosylation: considerations for optimal performance.

Haab BB, Partyka K, Cao Z.

Curr Protoc Protein Sci. 2013 Sep 24;73:Unit 27.6. doi: 10.1002/0471140864.ps2706s73.

17.

Characterization of glycoproteins in pancreatic cyst fluid using a high-performance multiple lectin affinity chromatography platform.

Gbormittah FO, Haab BB, Partyka K, Garcia-Ott C, Hancapie M, Hancock WS.

J Proteome Res. 2014 Jan 3;13(1):289-99. doi: 10.1021/pr400813u. Epub 2013 Dec 13.

18.

Prediction of glycan motifs using quantitative analysis of multi-lectin binding: Motifs on MUC1 produced by cultured pancreatic cancer cells.

McCarter C, Kletter D, Tang H, Partyka K, Ma Y, Singh S, Yadav J, Bern M, Haab BB.

Proteomics Clin Appl. 2013 Oct;7(9-10):632-41. doi: 10.1002/prca.201300069. Epub 2013 Sep 13.

19.

The developing schistosome worms elicit distinct immune responses in different tissue regions.

McWilliam HE, Driguez P, Piedrafita D, Maupin KA, Haab BB, McManus DP, Meeusen EN.

Immunol Cell Biol. 2013 Aug;91(7):477-85. doi: 10.1038/icb.2013.33. Epub 2013 Jul 16.

PMID:
23856766
20.

Specific glycoforms of MUC5AC and endorepellin accurately distinguish mucinous from nonmucinous pancreatic cysts.

Cao Z, Maupin K, Curnutte B, Fallon B, Feasley CL, Brouhard E, Kwon R, West CM, Cunningham J, Brand R, Castelli P, Crippa S, Feng Z, Allen P, Simeone DM, Haab BB.

Mol Cell Proteomics. 2013 Oct;12(10):2724-34. doi: 10.1074/mcp.M113.030700. Epub 2013 Jul 8.

21.

The Marker State Space (MSS) method for classifying clinical samples.

Fallon BP, Curnutte B, Maupin KA, Partyka K, Choi S, Brand RE, Langmead CJ, Tembe W, Haab BB.

PLoS One. 2013 Jun 4;8(6):e65905. doi: 10.1371/journal.pone.0065905. Print 2013.

22.

Global comparisons of lectin-glycan interactions using a database of analyzed glycan array data.

Kletter D, Singh S, Bern M, Haab BB.

Mol Cell Proteomics. 2013 Apr;12(4):1026-35. doi: 10.1074/mcp.M112.026641. Epub 2013 Feb 11.

23.

Modulation of glycan detection on specific glycoproteins by lectin multimerization.

Cao Z, Partyka K, McDonald M, Brouhard E, Hincapie M, Brand RE, Hancock WS, Haab BB.

Anal Chem. 2013 Feb 5;85(3):1689-98. doi: 10.1021/ac302826a. Epub 2013 Jan 16.

24.

Using lectins in biomarker research: addressing the limitations of sensitivity and availability.

Haab BB.

Proteomics Clin Appl. 2012 Aug;6(7-8):346-50. doi: 10.1002/prca.201200014. Review.

25.

Diverse monoclonal antibodies against the CA 19-9 antigen show variation in binding specificity with consequences for clinical interpretation.

Partyka K, Maupin KA, Brand RE, Haab BB.

Proteomics. 2012 Jul;12(13):2212-20. doi: 10.1002/pmic.201100676.

26.

Comparison of surgical and endoscopic sample collection for pancreatic cyst fluid biomarker identification.

Partyka K, McDonald M, Maupin KA, Brand R, Kwon R, Simeone DM, Allen P, Haab BB.

J Proteome Res. 2012 May 4;11(5):2904-11. doi: 10.1021/pr2012736. Epub 2012 Apr 4.

27.

Enhanced discrimination of malignant from benign pancreatic disease by measuring the CA 19-9 antigen on specific protein carriers.

Yue T, Maupin KA, Fallon B, Li L, Partyka K, Anderson MA, Brenner DE, Kaul K, Zeh H, Moser AJ, Simeone DM, Feng Z, Brand RE, Haab BB.

PLoS One. 2011;6(12):e29180. doi: 10.1371/journal.pone.0029180. Epub 2011 Dec 29.

28.

High-throughput studies of protein glycoforms using antibody-lectin sandwich arrays.

Haab BB, Yue T.

Methods Mol Biol. 2011;785:223-36. doi: 10.1007/978-1-61779-286-1_15.

29.

The fine specificity of mannose-binding and galactose-binding lectins revealed using outlier motif analysis of glycan array data.

Maupin KA, Liden D, Haab BB.

Glycobiology. 2012 Jan;22(1):160-9. doi: 10.1093/glycob/cwr128. Epub 2011 Aug 29.

30.

Identification of blood-protein carriers of the CA 19-9 antigen and characterization of prevalence in pancreatic diseases.

Yue T, Partyka K, Maupin KA, Hurley M, Andrews P, Kaul K, Moser AJ, Zeh H, Brand RE, Haab BB.

Proteomics. 2011 Sep;11(18):3665-74. doi: 10.1002/pmic.201000827. Epub 2011 Aug 2.

31.

S100A8/A9 deficiency in nonhealing venous leg ulcers uncovered by multiplexed antibody microarray profiling.

Trøstrup H, Lundquist R, Christensen LH, Jorgensen LN, Karlsmark T, Haab BB, Agren MS.

Br J Dermatol. 2011 Aug;165(2):292-301. doi: 10.1111/j.1365-2133.2011.10384.x.

PMID:
21517798
32.

Glycogene expression alterations associated with pancreatic cancer epithelial-mesenchymal transition in complementary model systems.

Maupin KA, Sinha A, Eugster E, Miller J, Ross J, Paulino V, Keshamouni VG, Tran N, Berens M, Webb C, Haab BB.

PLoS One. 2010 Sep 27;5(9):e13002. doi: 10.1371/journal.pone.0013002.

33.

Glycosylation variants of mucins and CEACAMs as candidate biomarkers for the diagnosis of pancreatic cystic neoplasms.

Haab BB, Porter A, Yue T, Li L, Scheiman J, Anderson MA, Barnes D, Schmidt CM, Feng Z, Simeone DM.

Ann Surg. 2010 May;251(5):937-45. doi: 10.1097/SLA.0b013e3181d7738d.

34.

Antibody-lectin sandwich arrays for biomarker and glycobiology studies.

Haab BB.

Expert Rev Proteomics. 2010 Feb;7(1):9-11. doi: 10.1586/epr.09.102. No abstract available.

35.

Antibody-array interaction mapping, a new method to detect protein complexes applied to the discovery and study of serum amyloid P interactions with kininogen in human plasma.

Bergsma D, Chen S, Buchweitz J, Gerszten R, Haab BB.

Mol Cell Proteomics. 2010 Mar;9(3):446-56. doi: 10.1074/mcp.M900418-MCP200. Epub 2009 Dec 18.

36.

A motif-based analysis of glycan array data to determine the specificities of glycan-binding proteins.

Porter A, Yue T, Heeringa L, Day S, Suh E, Haab BB.

Glycobiology. 2010 Mar;20(3):369-80. doi: 10.1093/glycob/cwp187. Epub 2009 Nov 29.

37.

The development of an integrated platform to identify breast cancer glycoproteome changes in human serum.

Zeng Z, Hincapie M, Haab BB, Hanash S, Pitteri SJ, Kluck S, Hogan JM, Kennedy J, Hancock WS.

J Chromatogr A. 2010 May 7;1217(19):3307-15. doi: 10.1016/j.chroma.2009.09.029. Epub 2009 Sep 16.

38.

Mucin glycosylation is altered by pro-inflammatory signaling in pancreatic-cancer cells.

Wu YM, Nowack DD, Omenn GS, Haab BB.

J Proteome Res. 2009 Apr;8(4):1876-86. doi: 10.1021/pr8008379.

39.

Antibody microarray analysis of serum glycans in esophageal squamous cell carcinoma cases and controls.

Shao C, Chen S, Chen L, Cobos E, Wang JS, Haab BB, Gao W.

Proteomics Clin Appl. 2009 Aug;3(8):923-31. doi: 10.1002/prca.200800245. Epub 2009 Jul 30. No abstract available.

PMID:
21136996
40.

Microarrays in glycoproteomics research.

Yue T, Haab BB.

Clin Lab Med. 2009 Mar;29(1):15-29. doi: 10.1016/j.cll.2009.01.001. Review.

41.

Analysis of glycans on serum proteins using antibody microarrays.

Chen S, Haab BB.

Methods Mol Biol. 2009;520:39-58. doi: 10.1007/978-1-60327-811-9_4.

42.

The prevalence and nature of glycan alterations on specific proteins in pancreatic cancer patients revealed using antibody-lectin sandwich arrays.

Yue T, Goldstein IJ, Hollingsworth MA, Kaul K, Brand RE, Haab BB.

Mol Cell Proteomics. 2009 Jul;8(7):1697-707. doi: 10.1074/mcp.M900135-MCP200. Epub 2009 Apr 17.

43.

Comprehensive proteome analysis of an Apc mouse model uncovers proteins associated with intestinal tumorigenesis.

Hung KE, Faca V, Song K, Sarracino DA, Richard LG, Krastins B, Forrester S, Porter A, Kunin A, Mahmood U, Haab BB, Hanash SM, Kucherlapati R.

Cancer Prev Res (Phila). 2009 Mar;2(3):224-33. doi: 10.1158/1940-6207.CAPR-08-0153. Epub 2009 Feb 24.

44.
45.

An experimental strategy for quantitative analysis of the humoral immune response to prostate cancer antigens using natural protein microarrays.

Forrester S, Qiu J, Mangold L, Partin A, Misek D, Phinney B, Whitten D, Andrews P, Diamandis E, Omenn GS, Hanash S, Haab BB.

Proteomics Clin Appl. 2007 May;1(5):494-505. doi: 10.1002/prca.200600802. Epub 2007 Apr 19.

46.

Multiplexed analysis of glycan variation on native proteins captured by antibody microarrays.

Chen S, LaRoche T, Hamelinck D, Bergsma D, Brenner D, Simeone D, Brand RE, Haab BB.

Nat Methods. 2007 May;4(5):437-44. Epub 2007 Apr 8.

PMID:
17417647
47.

Antibody array profiling reveals serum TSP-1 as a marker to distinguish benign from malignant prostatic disease.

Shafer MW, Mangold L, Partin AW, Haab BB.

Prostate. 2007 Feb 15;67(3):255-67.

PMID:
17192876
48.

Mass spectrometry-based study of the plasma proteome in a mouse intestinal tumor model.

Hung KE, Kho AT, Sarracino D, Richard LG, Krastins B, Forrester S, Haab BB, Kohane IS, Kucherlapati R.

J Proteome Res. 2006 Aug;5(8):1866-78.

PMID:
16889408
49.

A reagent resource to identify proteins and peptides of interest for the cancer community: a workshop report.

Haab BB, Paulovich AG, Anderson NL, Clark AM, Downing GJ, Hermjakob H, Labaer J, Uhlen M.

Mol Cell Proteomics. 2006 Oct;5(10):1996-2007. Epub 2006 Jul 24.

50.

Applications of antibody array platforms.

Haab BB.

Curr Opin Biotechnol. 2006 Aug;17(4):415-21. Epub 2006 Jul 11. Review.

PMID:
16837184

Supplemental Content

Support Center